Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
CRBU Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Caribou Biosciences, Inc.NASDAQ: CRBU
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $649K fell 44.3% year over year, behind the -28.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Depreciation & amortization amounted to 32.7% of revenue in FY2025, down 6.6 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -44.3% toward the trailing-twelve-month pace of -28.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.65M USD
- Year-over-year change
- -7.2%
- 4-year CAGR
- +38.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.65M | -7.2% |
| FY2024 | 2024-12-31 | 3.93M | +11.4% |
| FY2023 | 2023-12-31 | 3.53M | -3.2% |
| FY2022 | 2022-12-31 | 3.64M | +270.0% |
| FY2021 | 2021-12-31 | 984K | — |
Depreciation & Amortization vs competitors
How CRBU compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.6% is the 9th highest of 11, against a peer median of -1.3%.
- Depreciation & amortization amounts to 27.9% of revenue for CRBU, versus a peer median of 21.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.13M USD | -8.0% | -4.7% | — | |
| LTM Mar 2026 | $7.81M USD | -13.0% | +11.0% | 3469.8% | |
| LTM Mar 2026 | $6.86M USD | +34.4% | -13.4% | 340.1% | |
| LTM Mar 2026 | $4.95M USD | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $4.42M USD | +82.7% | +85.3% | 31.9% | |
| FY2025 | €3.22M EUR | -38.0% | +23.8% | 71.9% | |
| LTM Mar 2026 | $3.13M USD | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.84M USD | -8.0% | -25.0% | 10.1% | |
| LTM Mar 2026 | $1.53M USD | +180.4% | +0.4% | 9.2% | |
| LTM Mar 2026 | $718K USD | -3878.9% | — | — | |
| LTM Mar 2026 | $334K USD | +5.4% | +13.8% | 1.0% | |
| Peer median (excluding CRBU) | — | -1.3% | +11.0% | 21.0% | |
Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (66.92M) | (99.42M) | (102.07M) | (149.11M) | (148.13M) |
| Depreciation & Amortization | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| Deferred Income Tax | 0 | (95K) | 0 | 0 | (548K) |
| Stock-Based Compensation | 3.45M | 11.72M | 13.75M | 16.71M | 12.68M |
| Change in Working Capital | 29.07M | (4.11M) | (7.32M) | (5.11M) | (484K) |
| Accounts Receivables | (2.96M) | 3.46M | 805K | 608K | 272K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.14M | (2.72M) | 1.82M | (354K) | 3.25M |
| Other Working Capital | 30.89M | (4.85M) | (9.94M) | (5.37M) | (4.01M) |
| Other Non-Cash Items | 904K | 9.02M | (1.18M) | (4.61M) | 21.84M |
| Operating Cash Flow | (32.52M) | (90.97M) | (93.29M) | (138.2M) | (110.99M) |
| Capital Expenditures | (3.12M) | (6.45M) | (11.61M) | (6.51M) | (1.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (173.28M) | (339.06M) | (394.76M) | (304.39M) | (150.37M) |
| Sales of Investments | 0 | 252.87M | 338.19M | 397.49M | 252.83M |
| Other Investing Activities | (1M) | (600K) | 0 | (1.61M) | 1.14M |
| Investing Cash Flow | (176.4M) | (93.25M) | (68.18M) | 86.61M | 102.24M |
| Debt Repayment | 1.03M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 321.02M | 2.13M | 152.72M | 15.19M | 4.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.55M | 0 | 1.58M | 1.53M | 0 |
| Financing Cash Flow | 433.43M | 2.13M | 154.3M | 16.72M | 4.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 224.51M | (182.08M) | (7.18M) | (34.87M) | (3.93M) |
| Free Cash Flow | (35.64M) | (97.42M) | (104.9M) | (144.71M) | (112.35M) |
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.